NurExone Biologic (NRX): The Inhibitor of the Inhibitor: How Nurexone's ExoPTEN Is Designed to Restart Nerve Regeneration

In this episode of Healthcare Happenings, Robert Sassoon, WTR healthcare equity analyst, joins host Tim Gerdeman to discuss his initiation of coverage on NurExone Biologic (TSXV: NRX / OTCQB: NRXBF), a preclinical biopharma company advancing a novel exosome platform targeting CNS regeneration. Sassoon walks through the science behind exosome therapeutics, NurExone's differentiated ExoTherapy platform and lead asset ExoP10, which combines a natural exosome carrier with an RNA payload designed to silence the P10 gene and unlock nerve regeneration in acute spinal cord and optic nerve injury. The conversation also covers the company's vertical integration strategy through its Exotop subsidiary and U.S. master cell bank, the LOI with Florida-based BioXTech for GMP manufacturing capacity, and the key milestones investors should track, including IND submission, compassionate use access, first commercial exosome revenue, and a potential U.S. mainboard listing.